|Articles|February 22, 2021

COVID-19 Coalition Offers Insights into Vaccine Rollout, Double-Masking

This partnership of recognized experts provided feedback about a variety of topics related to the virus.

The MJH Life Sciences COVID-19 Coalition offered its insights on a number of coronavirus 2019 (COVID-19) topics including the vaccine rollout, the Biden administration’s goal of 100 million shots in the first 100 days, double masking, and vaccine hesitancy.

The COVID-19 Coalition is a partnership with 10 nationally recognized experts in infectious disease, public health, epidemiology, and virology, who work to generate the most accurate, up-to-the-minute information on the pandemic's ever-evolving impact on health care professionals and the patients they treat through live, biweekly webinar events, white papers, and surveys.

The coalition was surveyed on a number of topics related to COVID-19. Check out the slideshow to learn more about their insights.

The next COVID-19 Coalition webinar, “Legal and Ethical Considerations of COVID-19 Vaccination,” will be held this Wednesday, February 24 at 6PM ET. Register here.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Related to this article

October 25th, 2026

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants

Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.

October 25th, 2026

Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record

CDC says the Bundibugyo virus outbreak in the DRC is the second-largest Ebola outbreak on record, with 9735 confirmed cases and 4690 deaths.

Alisse Hannaford, MD (Image Credit: Mass General)

October 24th, 2026

Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events

Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.

October 24th, 2026

Asuptegravir Lowers HIV-1 RNA up to 2.36 Logs in Early Monotherapy

Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.

Paul Feuerstadt, MD (Credit: Physicians Alliance of Connecticut)

October 24th, 2026

Fecal Microbiota Spores Cut Early Hospitalizations in Recurrent C diff

In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.

October 24th, 2026

CDC Tracking 5 Active Food-Borne Outbreaks Tied to Oysters, Cheese, Sprouts

CDC lists 5 active multistate outbreaks tied to oysters, raw milk cheese, sprouts, and pet turtles, with recalls in effect for 4 of them.

October 24th, 2026

Ensitrelvir PEP Eases Symptom Severity in COVID-19 Breakthrough Cases

Exploratory SCORPIO-PEP data presented at IDWeek 2026 show household contacts with breakthrough COVID-19 on ensitrelvir had lower peak viral RNA and fewer severe symptoms than placebo recipients.

John H. Rex, MD, chief medical officer of F2G

October 23rd, 2026

Oral Olorofim Noninferior to AmBisome in Phase 3 OASIS Trial

Day 42 all-cause mortality was 23.8% with oral olorofim vs 24.3% with AmBisome plus standard of care in invasive aspergillosis unsuited to azole therapy.

COVID-19 Coalition Offers Insights into Vaccine Rollout, Double-Masking

Related to this article

Trending on Contagion Live

Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria

Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1

Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events

Asuptegravir Lowers HIV-1 RNA up to 2.36 Logs in Early Monotherapy

Ensitrelvir PEP Eases Symptom Severity in COVID-19 Breakthrough Cases